Modeling of valspodar (PSC 833) in elderly patients with acute myeloid leukemia (AML)

被引：0
|
作者：
Uyl-de Groot, CA [1 ]
McDonnell, J [1 ]
Wait, S [1 ]
机构：
[1] Erasmus Univ, IMTA, Rotterdam, Netherlands
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 1998年 / 102卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：225 / 225
页数：1
相关论文
共 50 条
  • [1] A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia
    Gruber, A
    Björkholm, M
    Brinch, L
    Evensen, S
    Gustavsson, B
    Hedenus, M
    Juliusson, G
    Löfvenberg, E
    Nesthus, I
    Simonsson, B
    Sjo, M
    Stenke, L
    Tangen, JM
    Tidefelt, U
    Udén, AM
    Paul, C
    Liliemark, J
    [J]. LEUKEMIA RESEARCH, 2003, 27 (04) : 323 - 328
  • [2] Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)
    Advani, R
    Visani, G
    Milligan, D
    Saba, H
    Tallman, M
    Rowe, JM
    Wiernik, PH
    Ramek, J
    Dugan, K
    Lum, B
    Villena, J
    Davis, E
    Paietta, E
    Litchman, M
    Covelli, A
    Sikic, B
    Greenberg, P
    [J]. DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA III, 1999, 457 : 47 - 56
  • [3] P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with p-glycoprotein-positive acute myeloid leukemia
    Tidefelt, U
    Liliemark, J
    Gruber, A
    Liliemark, E
    Sundman-Engberg, B
    Juliusson, G
    Stenke, L
    Elmhorn-Rosenborg, A
    Möllgård, L
    Lehman, S
    Xu, D
    Covelli, A
    Gustavsson, B
    Paul, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (09) : 1837 - 1844
  • [4] Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia
    G Visani
    D Milligan
    F Leoni
    J Chang
    S Kelsey
    R Marcus
    R Powles
    S Schey
    A Covelli
    A Isidori
    M Litchman
    PP Piccaluga
    H Mayer
    M Malagola
    C Pfister
    [J]. Leukemia, 2001, 15 : 764 - 771
  • [5] Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia
    Visani, G
    Milligan, D
    Leoni, F
    Chang, J
    Kelsey, S
    Marcus, R
    Powles, R
    Schey, S
    Covelli, A
    Isidori, A
    Litchman, M
    Piccaluga, PP
    Mayer, H
    Malagola, M
    Pfister, C
    [J]. LEUKEMIA, 2001, 15 (05) : 764 - 771
  • [6] INTENSIVE CHEMOTHERAPY FOR ELDERLY PATIENTS WITH ACUTE MYELOID-LEUKEMIA (AML)
    YIN, JAL
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1992, 82 (01) : 279 - 279
  • [7] Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (Valspodar)
    Advani, R
    Saba, HI
    Tallman, MS
    Rowe, JM
    Wiernik, PH
    Ramek, J
    Dugan, K
    Lum, B
    Villena, J
    Davis, E
    Paietta, E
    Litchman, M
    Sikic, BI
    Greenberg, PL
    [J]. BLOOD, 1999, 93 (03) : 787 - 795
  • [8] Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia
    Dorr, R
    Karanes, C
    Spier, C
    Grogan, T
    Greer, J
    Moore, J
    Weinberger, B
    Schiller, G
    Pearce, T
    Litchman, M
    Dalton, W
    Roe, D
    List, AF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) : 1589 - 1599
  • [9] A Randomized comparison of induction therapy for untreated acute myeloid leukemia (AML) in patients <60 years using P-Glycoprotein (Pgp) modulation with valspodar (PSC833):: Preliminary results of cancer and leukemia group B study 19808.
    Kolitz, JE
    George, SL
    Marcucci, G
    Vij, R
    Powell, BL
    Allen, SL
    De Angelo, DJ
    Shea, T
    Stock, W
    Hars, V
    Hoke, E
    Vardiman, JW
    Bloomfield, CD
    Larson, RA
    [J]. BLOOD, 2005, 106 (11) : 122A - 123A
  • [10] Genomic landscape of Acute Myeloid Leukemia (AML) in the elderly
    Panina, E.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 301 - 301
12345